BioAtla has placed 10 500 000 shares of common stock in an IPO priced $18 per share, which is $1 above the upper limit of the previously announced range ($15-17). Besides, BioAtla has granted the underwriters a 30-day option to purchase up to 1 575 000 shares of common stock at the public offering price.
The trading debut will take place on the Nasdaq Global Select Market on December 16, 2020 under the ticker symbol “BCAB”.